Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
This study has been completed.
Study NCT00426530   Information provided by Novartis

First Received on January 23, 2007.   Last Updated on October 6, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Neoplasms
Neoplasm Metastasis
Additional conditions recognized in this trial
Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Neoplastic Processes
Pathologic Processes
Skin Diseases
Interventions listed in this trial
everolimus (RAD001)
Additional drug interventions recognized in this trial
Everolimus
Sirolimus
Trastuzumab
Vinorelbine
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services